f-3

3'-F-3'-dA(Bz)-2'-phosphoramidite is a fluoro-modified nucleoside derivative used as a nucleoside phosphoramidite.

3'-F-3'-dG(iBu)-2'-phosphoramidite is a Nucleoside Phosphoramidite.

Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

Osimertinib mesylate (AZD-9291 mesylate) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib mesylate has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

Calcium glycerophosphate(CaGP) is an inhibitor of intestinal alkaline phosphatase F3. Calcium glycerophosphate can be a source of calcium and phosphorus in total parenteral nutrition solutions [1] [2].

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.

Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).

F3-PEG8-RiboTAC is a RiboTAC compound that specifically degrades the mRNA of the oncogene LGALS1. This compound can induce apoptosis (cell death) in tumor cells and inhibit their invasion. F3-PEG8-RiboTAC exhibits antitumor activity and is applicable in research on leukemia and triple-negative breast cancer. (RNase L ligand; RNA binder; Linker)

Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, with KDs of 0.2, 0.76, 13, and 1.2 nM for EGFR, HER2, BLK, and RIPK2, respectively, and exhibits anticancer activity.

Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a human-derived antibody expressed in CHO cells, targeting F3/Factor III/Tissue Factor/CD142. It possesses a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to [HumanIgG4kappa, Isotype Control].

DSPE-PEG5000-F3 consists of DSPE and the nucleolin-targeting peptide (F3) and is a PEGylated compound. The F3 peptide specifically binds to nucleolin on the cell surface, facilitating efficient transport from the cell surface to the nucleus. DSPE-PEG5000-F3 is applicable for drug delivery.

DSPE-PEG1000-F3 is a PEG compound made from DSPE and a targeting peptide called nucleolin (F3). The F3 peptide can specifically bind to cell surface nucleolin, enabling efficient transport from the cell surface to the nucleus. DSPE-PEG1000-F3 is applicable in drug delivery.

DSPE-PEG2000-F3 is a PEG compound composed of DSPE and the nucleolin-targeting peptide (F3). The F3 peptide can specifically bind to nucleolin on the cell surface, facilitating efficient transport from the cell surface to the nucleus. DSPE-PEG2000-F3 is applicable for drug delivery.

DSPE-PEG3400-F3 is a PEG-modified compound composed of DSPE and the nucleolin-targeting peptide (F3). The F3 peptide has the ability to specifically bind to cell surface nucleolin and facilitate efficient transport from the cell surface to the nucleus. DSPE-PEG3400-F3 is applicable in drug delivery.

Ginsenoside F3 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside F3. Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).

F3 peptide is a fragment of human high mobility group protein 2 (HMGB2) that specifically binds to nucleolin, expressed on the membranes of cancer cells, neovasculature, and endothelial cells. Serving as an effective ligand, F3 peptide enhances the druggability of macromolecular drugs or nanoparticles.

STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.

AF-399/42018025 is a small-molecule antagonist of CC chemokine receptor 4 (CCR4) utilized as a research tool to investigate CCR4-mediated immune cell trafficking, inflammatory signaling, and chemokine-driven disease mechanisms, supporting studies in immunology, oncology, and inflammatory disorder models.

PF-3450074 (PF-74) acts at an early stage of HIV-1 infection inhibits viral replication by directly competing with the binding of CPSF6 (nuclear host factors cleavage and polyadenylation specific factor 6) and NUP153 (nucleoporin 153), and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle. PF-3450074 is a specifical inhibitor of HIV-1 capsid protein (CA) and shows a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM).

AF-353 (Ro-4), an effective and orally bioavailable antagonist of the P2X3/P2X2/3 receptor, inhibits human and rat P2X3 (pIC50= 8.0).

GNF-PF-3777 (8-Nitrotryptanthrin) is a potent inhibitor of human indoleamine 2,3-dioxygenase 2 (hIDO2) with a Ki of 0.97 μM.

SKF-34288 hydrochloride (3-Mercaptopicolinic acid hydrochloride) is an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK),and inhibits Asn metabolism and results in an increase in amino acids and amides.

PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated/activated

PF-3882845 is an orally available and selective salicorticoid receptor (MR) antagonist that binds to the progesterone receptor (PR) and can be used to study endocrine diseases and urogenital disorders.